Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 1300 (2008)
doi:10.1038/nm1208-1300b
Biomedical sector takes steps to handle harsh financial realities
Meredith Wadman1
- Washington, DC
The financial crisis has not been kind to the pharmaceutical and biotechnology sectors, with prominent names such as Merck and DeCode Genetics taking recent blows.DeCode, the pioneering Icelandic genetics and genomics company, watched its share price plunge from a 52-week high of $4.
To read this story in full you will need to login or make a payment (see right).
